Kit for assisting in detection of placenta implantation and application thereof

An auxiliary detection and detection reagent technology, applied in the field of molecular biology, can solve the problems of no placenta accreta, high technical requirements, low specificity, etc., and achieve the effect of improving accuracy and fast detection means

Inactive Publication Date: 2019-04-02
THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Non-invasive serological screening methods are being further developed. It has been reported that serum AFP has a significant correlation with placenta accreta, but its specificity is not high, and it has not yet been developed into a clinically applicable detection kit.
Analysis of placental free mRNA in maternal plasma in the first trimester can predict placenta accreta, but it requires high technical means, and there is no clinical application at present
In addition, studies have reported that fetal cell-free DNA in plasma is elevated in peripheral blood of placenta accreta, but the clinical significance is not clear
Therefore, there is currently no method available for clinical application that uses biomarkers in maternal blood to assist in the detection of placenta accreta

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for assisting in detection of placenta implantation and application thereof
  • Kit for assisting in detection of placenta implantation and application thereof
  • Kit for assisting in detection of placenta implantation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] 1. Materials and equipment

[0030] Kit: Bio-Plex Assay 171AC600M; instrument model: Bio-Plex 200; vortex mixer; refrigerated centrifuge suitable for 1.5-2ml centrifuge tubes; microplate shaker (up to 500rpm); magnetic separation plate ( Hand-Held Magnetic Plate Washer); 2μl-1000μl single-channel pipette; 20μl-300μl multi-channel pipette; multi-channel pipette reservoir; deionized water, beaker, test tube, absorbent paper, etc.

[0031] 2. Collection of peripheral blood samples

[0032] After obtaining consent, collect non-anticoagulated peripheral blood serum from suspected cases and 30-50 cases of normal delivery pregnant women before delivery, coagulate at room temperature for 30-45 minutes, and centrifuge at 1000g at 4°C for 15 minutes. minutes, and then transferred to cryopreservation tubes. Store in a -80°C ultra-low temperature freezer. After the samples were collected, 50 μl of serum was frozen and thawed at 4°C, and centrifuged repeatedly at 1000 g for 10 mi...

Embodiment 2

[0106] Using the same method as in Example 1, the non-anticoagulant peripheral blood serum collected before delivery was collected from pregnant women who were diagnosed as false positive by other methods before delivery, and from pregnant women who were pathologically diagnosed with placenta previa combined with placenta accreta. Perform VEGF-A concentration detection:

[0107] The first group of pregnant women with false positive prepartum diagnosis results were: pregnant women with placenta previa diagnosed by ultrasound but no placenta accreta occurred after delivery.

[0108] Test results such as Figure 7-8 shown, where Figure 7 P is the relative concentration of VEGF-A, P is the pregnant woman with placenta previa diagnosed by ultrasound but no placenta accreta, and PA-3 is the pregnant woman with placenta previa diagnosed by ultrasound and placenta accreta confirmed by pathology. Figure 8 is the ROC curve and its AUC value. The results showed that a cut-off value ...

Embodiment 3

[0113] According to the method described in Example 1, after obtaining consent, the VEGF-A concentration in the antepartum peripheral serum of 38 cases of normal delivery pregnant women from January 2017 to December 2017 was detected, and the average value was 423.0389. The average value is the reference normal value. Calculate the detection value / reference value ratio of 10 suspected cases from January 2017 to December 2017. The results are shown in Table 3:

[0114] Table 3 Application of VEGF-A detection in auxiliary diagnosis of placenta accreta

[0115]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention applies an agent capable of detecting VEGF-A concentration to detect peripheral blood of pregnant women. The VEGF-A concentration of peripheral serum of a normal delivery pregnant womanbefore delivery is taken as a reference value, peripheral blood of a pregnant woman to be detected is taken as a detection value, and the detection value/reference value is taken as a cutoff value by1.0 to prepare a kit for assisting in the detection of placenta implantation. The kit not only has medium-intensity discrimination performance for pregnant women with placenta implantation and pregnant women with normal delivery, but also has medium-intensity discrimination performance for pregnant women with placenta implantation and pregnant women whose assisting diagnosis result is a false positive by using other methods. The kit provides a convenient and quick assisting detection method. Concentration data obtained by detection is used as a reference value, which can be combined with results of other methods, and is beneficial to improve accuracy of risk screening for pregnant women with placenta implantation.

Description

technical field [0001] The invention belongs to the technical field of molecular biology, in particular to a kit for assisting detection of placenta accreta and its application. Background technique [0002] Placenta accreta refers to a disease in which the placental villi invade part of the myometrium, and the placental villi are intricately scattered and implanted in the uterine muscle wall. It is a rare but critical complication in obstetrics, which can lead to massive bleeding, shock, uterine perforation and infection, and even death. Placenta accreta has been reported in recent years with an incidence rate of 4 / 1000 among pregnant women. Among them, placenta previa combined with placenta accreta has a high incidence, large amount of clinical bleeding, and high mortality, which is called dangerous placenta accreta. [0003] At present, there is still a lack of simple and effective early screening or auxiliary diagnostic techniques for placenta accreta before delivery, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/74
CPCG01N33/74
Inventor 余波澜陈敦金
Owner THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap